Diaceutics PLC
PDMR Shareholding/Share Incentive Plan and Total Voting Rights
New York, Belfast and London, 4 November 2026 - Diaceutics PLC (AIM: DXRX), the intelligence and engagement company unlocking the full potential of diagnostic-driven therapies, has been notified that on 29 October 2026, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of £0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark and Nick Roberts (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.
In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.
As announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. The matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled by the Company issuing 3,896 Shares on 3 November 2026 to the UK Trust. The Trust will hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.
During the period from the last Total Voting Rights Announcement on 6 October 2026, 53,810 Shares were allotted to settle certain employee share option exercises during September 2026 in addition to the Shares allotted as a result of the Share Incentive Plan transactions announced today. As a result, the number of Shares Diaceutics has in issue is 85,291,958. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
|
Diaceutics PLC |
|
|
Ryan Keeling, Chief Executive Officer |
Tel: +44 (0)28 9040 6500 |
|
Nick Roberts, Chief Financial Officer |
investorrelations@diaceutics.com |
|
Canaccord Genuity Limited (Nomad & Broker) |
Tel: +44 (0)20 7253 8000 |
|
Simon Bridges, Andrew Potts, Harry Rees |
|
About Diaceutics
At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a. |
Name |
Susanne Munksted |
|||
|
2 |
Reason for notification |
||||
|
a. |
Position/Status |
Chief Growth Officer |
|||
|
b. |
Initial notification/ Amendment |
Initial |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a. |
Name |
Diaceutics PLC |
|||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 |
|||
|
b. |
Nature of the transaction |
Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP") |
|||
|
c. |
Price(s) and volume(s) |
Share purchase: |
|||
|
Price(s) |
Volume(s) |
||||
|
203.8 p |
71 |
||||
|
Conditional share award: |
|||||
|
Price(s) |
Volume(s) |
||||
|
Nil |
71 |
||||
|
e. |
Date of the transaction |
Share purchase and Conditional share award: 29 October 2026 |
|||
|
f. |
Place of the transaction |
Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market |
|||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
Jordan Clark |
|||||
|
2 |
Reason for notification |
||||||
|
a. |
Position/Status |
Chief Customer Officer |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") |
|||||
|
c. |
Price(s) and volume(s) |
Share purchase: |
|||||
|
Price(s) |
Volume(s) |
||||||
|
203.8 p |
74 |
||||||
|
Matched share award: |
|||||||
|
Price(s) |
Volume(s) |
||||||
|
Nil |
74 |
||||||
|
e. |
Date of the transaction |
Share purchase and Matched Share award: 29 October 2026 |
|||||
|
f. |
Place of the transaction |
Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market |
|||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
|
a. |
Name |
Nick Roberts |
|||||
|
2 |
Reason for notification |
||||||
|
a. |
Position/Status |
Chief Finance Officer |
|||||
|
b. |
Initial notification/ Amendment |
Initial |
|||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a. |
Name |
Diaceutics PLC |
|||||
|
b. |
LEI |
213800VEWQBB39ZB8J81 |
|||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.002 each ISIN: GB00BJQTGV64 |
|||||
|
b. |
Nature of the transaction |
Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP") |
|||||
|
c. |
Price(s) and volume(s) |
Share purchase: |
|||||
|
Price(s) |
Volume(s) |
||||||
|
203.8 p |
74 |
||||||
|
Matched share award: |
|||||||
|
Price(s) |
Volume(s) |
||||||
|
Nil |
74 |
||||||
|
e. |
Date of the transaction |
Share purchase and Matched Share award: 29 October 2026 |
|||||
|
f. |
Place of the transaction |
Share Purchase: AIM Market of the London Stock Exchange Matched Share Award: Off-Market |
|||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.